Transplant patients test simpler daily pill
NCT ID NCT02882828
Summary
This study tested whether switching kidney or liver transplant patients from a twice-daily anti-rejection pill to a newer once-daily version provides the same level of drug in the body. Researchers measured drug levels in 134 patients before and after the switch to see if the once-daily pill maintained proper protection against organ rejection. The goal was to confirm if the simpler dosing schedule works just as effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGRAFT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP
Paris, France
-
Limoges Hospital
Limoges, 87 042, France
-
University Hospital of Amiens
Amiens, France
-
University Hospital of Bordeaux
Bordeaux, France
-
University Hospital of Lille
Lille, France
-
University Hospital of Poitiers
Poitiers, France
-
University Hospital of Reims
Reims, France
-
University Hospital of Rouen
Rouen, France
-
University Hospital of Tours
Tours, France
Conditions
Explore the condition pages connected to this study.